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Preimplantation genetic diagnosisTranslocation is one of the more common structural rearrangements of chromosomes, with a prevalence of 0.2%.
The two most common types of chromosomal translocations, Robertsonian and reciprocal, usually result in no
obvious phenotypic abnormalities when balanced. However, these are still associated with reproductive risks,
such as infertility, spontaneous abortion and the delivery of babies with mental retardation or developmental
delay.
In recent years, array-based whole-genome ampliﬁcation (WGA) technologies, including microarray compara-
tive genomic hybridization (array CGH; aCGH) and single-nucleotide polymorphism (SNP) micro-arrays, have
enabled the screening of every chromosome for whole-chromosome aneuploidy and segmental imbalance.
These techniques have been shown to have clinical application for translocation carriers. Promising studies
have indicated that array-based PGD of translocation carriers can lead to transfer pregnancy rates of 45–70% [2].
In addition to genetic testing techniques, the embryo biopsy stage (polar body, cleavage embryo or blastocyst)
and the mode of embryo transfer (fresh or frozen embryos) can affect the outcome of PGD. It is now generally
recommended that blastomere biopsy should be replaced by blastocyst biopsy to avoid a high mosaic rate and
biopsy-related damage to cleavage-stage embryos, which might affect embryo development. However, more
clinical data are required to conﬁrm that the technique of SNP array-based PGD (SNP-PGD) combined with
trophectoderm (TE) biopsy and frozen embryo transfer (FET) is superior to traditional FISH-PGD combined
with Day 3 (D3) blastomere biopsy and fresh embryo transfer.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).esearch Center of Human Stem
ax: +86 731 84497661.
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Experimental design, materials and methods
Study design and clinical information
To establish SNP array analysis for TE cells, we designed the study in
two stages. In Stage 1, we collected one cell and ﬁve cells from two
human embryonic stem cell (hESC) lines with a normal female karyo-
type and a trisomy 21 female karyotype, and 15 blastocysts donated
by 13 coupleswith Robertsonian or reciprocal translocation undergoing
FISH-PGD. The donated blastocysts were either diagnosed as ‘abnormal’
or ‘normal’ but with poor morphology. TEwas re-biopsied for two partsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. The validation of whole genome ampliﬁcation (WGA). The quality of theWGADNA
can be qualitatively determined by loading 2.5μL of the ﬁnal products onto a 1.5% agarose
gel. The DNA with good quality showed a size range of 100–1000 bp, with a mean size of
~400 bp. The poor quality DNA (lane 8, with arrow) has a size range lower than average,
from 50 to 800 bp, such WGA DNA cannot pass the quality control of SNP-array, and may
lead to failure of analysis.
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analysis, the second part was used for later validation by FISH.
In Stage 2, the established SNP array platformwas used for SNP-PGD
diagnosis. In total, 169 couples received PGD treatment between Octo-
ber 2011 and August 2012 in the Reproductive and Genetic Hospital of
Citic-Xiangya, because either the husband or the wife of each couple
carried a Robertsonian or reciprocal translocation according to conven-
tional karyotype analysis. The clinical manifestation of these couples
included primary or secondary infertility, a history of recurrent sponta-
neous abortion or a previous delivery of babies with congenital birth
defects. Among the 169 couples who received SNP-PGD therapy, 52
were Robertsonian translocation carriers and 117were reciprocal trans-
location carriers. Themeanmaternal age was 31.7 ± 5.02 years (range:
20–40 years old) for Robertsonian translocation carriers and 30.8 ±
4.74 years (range: 21–41 years old) for reciprocal translocation carriers.
The clinical information of SNP-PGD patients is seen in Table 1.
Before undergoing PGD cycles, all participants accepted genetic
counseling, understood the genetic risk of chromosome translocation
and the advantages and limitations of PGD therapy and provided writ-
ten informed consent. The ethical committee of the Reproductive and
Genetic Hospital of Citic-Xiangya approved the SNP-PGD program.
Blastocyst vitriﬁcation and thawing
Blastocysts were vitriﬁed soon after the biopsy using a Kitazato vit-
riﬁcation kit (Kitazato Biopharma Co. Ltd, Shizuoka, Japan) in combina-
tion with closed High Security Vitriﬁcation Straws (Cryo Bio System,
France). Each blastocyst was stored in an individual straw. The vitriﬁca-
tion and thawing procedure was carried out according to the protocol
recommended by the Kitazato vitriﬁcation kit. For the FET cycle, we
transferred no more than two blastocysts, and we recommended
single-blastocyst transfer to each patient. According to the number of
blastocysts to be thawed, we prioritized the blastocyst for thawing
based on the best quality before biopsy. After thawing, blastocysts
were transferred to a blastocyst medium and cultured for 1–2 h. Only
blastocysts that survived thawing and re-expanded were considered
suitable for transfer.
Embryo culture and biopsy
Pituitary desensitization followed by controlled ovarianhyperstimu-
lation was performed on these patients to achieve multiple follicle
growths. Oocytes were retrieved and fertilized by intracytoplasmic
sperm injection. The resulted embryos were further cultured in sequen-
tialmedia (G1 andG2, Vitrolife, Goteborg, Sweden) under 6% CO2, 5% O2
and 89% N2 in a COOK mini-incubator (Bloomington, IN, USA) for
further manipulation.
For the TE biopsy, an 18-mmhole wasmade in the zona pellucida of
all embryos. On D5 or D6 after fertilization, blastocysts in which TE cells
had herniated out of the zona pellucidawere chosen for biopsy. Approx-
imately 4–8 TE cells were aspirated with a biopsy pipette (internalTable 1
The clinical information of SNP-PGD patients.
R
Biopsied cycles 5
Maternal age (mean ± SD)a 3
No. of male carrier 3
No. of female carrier 2
Oocyte number 1
Blastocyst number on D5 4
Number of good blastocysts on D5 2
Biopsied embryos (median (range)) 4
Transferrable embryos per patient b (median (range)) 2
Cycles with all biopsied embryos diagnosed abnormal 5
a Data are mean ± SD or n (%) unless stated otherwise.
b Transferrable embryos per patient also refer to median normal/balanced embryos pdiameter: 30 mm) and dissected with Zilos TK laser (Hamilton Thorne,
MA, USA). Biopsied TE cells were washed three times in a G-MOPS
medium (Vitrolife,Goteborg, Sweden) and then either used directly for
WGA or stored at−20 °C for future WGA.
Whole genome ampliﬁcation
Biopsied samples were ﬁrst subjected to WGA using a WGA4
Genome-Plex Single Cell Whole Genome Ampliﬁcation kit (Sigma-
Aldrich, MO, USA) as previously described [1]. Brieﬂy, samples
were incubated at 50 °C for 1 h in a single-cell lysis and fragment
buffer, heated to 99 °C and then universal oligonucleotide primers
were used for PCR ampliﬁcation (25 cycles) of DNA fragments, accord-
ing to the manufacturer's recommendations. The quality of the WGA
DNA can be qualitatively determined by loading 5–10% (4–8 μL) of the
ﬁnal reaction onto a 1.5% agarose gel. The DNA size should range from
100 to 1000 bp, with a mean size of ~400 bp. WGA DNA was puriﬁed
using the Wizard SV Gel and PCR Clean-Up System PCR Puriﬁcation
kit (Promega, WI, USA). Fig. 1 shows the validation of WGA.
SNP array analysis
Two hundred and ﬁfty nanograms of puriﬁed WGA products were
then used for SNP array screening for chromosomal abnormalities, in-
cluding aneuploidy and unbalanced segment anomalies, affecting all
chromosomes except for the Y chromosome. Individual embryonic
DNA samples were hybridized to a GeneChip Mapping Nsp I 262Kobertsonian translocation Reciprocal translocation
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1.7 ± 5.02 30.8 ± 4.74
2 (62%) 55 (47%)
0 (38%) 62 (53%)
4.8 ± 6.44 14.9 ± 7.60
.9 ± 3.46 5.6 ± 3.38
.3 ± 2.52 2.7 ± 2.35
(1–15) 4 (1–14)
(0–6) 1 (0–6)
(10%) 35 (30%)
er patients.
Table 2
Result of SNP-PGD in chromosomal translocation carriers.
Embryology Robertsonian translocation Reciprocal translocation
Successfully biopsied 237 536
Successfully tested 218 (92%) 499 (93%)
Tested failure 19 (8%) 37 (7%)
Transferrable 126 (58%) 177 (36%)
Embryos with chromosomal imbalance 92 (42%) 322 (65%)
Translocation-related imbalance 51 (23%) 261 (52%)
Unbalanced translocation 37 (17%) 206 (41%)
Unbalanced translocation and de novo aneuploidy 8 (4%) 38 (8%)
Unbalanced translocation and de novo segmental abnormality 6 (3%) 16 (3%)
Translocation-unrelated imbalance 41 (19%) 62 (12%)
De novo aneuploidy 21 (10%) 29 (6%)
De novo segmental 9 (4%) 17 (3%)
De novo aneuploidy and segmental abnormality 4 (2%) 6 (1%)
Complex aneuploidy 7 (3%) 10 (2%)
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260,000 SNP signal intensities for each test samplewere computational-
ly compared with averaged signals from the reference database. For
SNP-typing,we analyzed probe intensities by the ‘GeneChip Genotyping
Analysis Software (GTYPE) version 4.1 (Affymetrix)’ using the dynamic
model, and adjusted the ‘Parameter Value’ for ‘Homozygote Call
Threshold’ as well as for ‘Heterozygote Call Threshold’ to 0.33.
For SNP-copy number analysis, we used the ‘Copy Number Analysis
Tool’ (CNAT4.0.1, Affymetrix), and set smoothing size to 16 megabases
(Mb) to eliminate background signals as previously recommended; the
minimum size of imbalance was reported to be 2.36 Mb [2,3]. The copy
number state of each chromosome was interpreted by a ﬁve-state Hid-
den Markov model with prior probabilities set equal for all ﬁve states.
Standard deviation settings were 0.11 for hidden-states zero, one,
three and four, while 0.08 for hidden-state 2. We set the transitionFig. 2.Anexample of SNP-PGD for a single Robertsonian translocation carrierwith a karyotype o
assignments (0, 1, 2, 3, or 4) on the y-axis and the arrows indicate the abnormal chromosomes, t
the chromosomeswith unique LOHprobability distributions. The chromosomenumber is indica
were normal/balanced embryos. E2 and E3 were abnormal embryos. E2 was a monosomy 6 (
(119,769-170,716,684) × 1. E3 was a monosomy 13 (arrow). The SNP array result was arr13q
the LOH probability of the SNPs toward 1 on the graph (i.e., complete LOH).decay at 4000 Mb, readjusted outliers using a threshold of 1000 bp
and allowed outliers to be readjusted.
In Stage 1, we selected 44 normal female SNP data from theHapMap
database to generate reference database. In Stage 2, the reference data-
base initially consisted of the above HapMap data and seven normal fe-
male SNP data from Stage 1. Then, the reference database was gradually
supplemented with new SNP data from late diagnosed normal female
by SNP array analysis. Copy number and loss of heterozygosity (LOH)
were analyzed by using the GeneChip Genotyping Analysis Software
(GTYPE). Y chromosome-speciﬁc PCR was performed to distinguish
the normal male karyotype from Y chromosome loss, as the SNP array
is unable to detect Y chromosome. The results of SNP-PGD were
summarized in Table 2. The SNP array results of blastocysts from a
Robertsonian translocation carrier and a reciprocal translocation carrier
were displayed in Figs. 2 and 3.f 45,XX,der(13;14)(q10;q10). The upper part of each graph indicates the SNP copynumber
he lower part indicates the SNP LOHprobability (0–1) on the y-axis and the arrows indicate
ted for both graphs on the x-axis. E1–E4 represent 4 blastocysts from the patient. E1 and E4
arrow) unrelated to Robertsonian translocation. The SNP array result was arr6p25.3q27
12.11q34 (17,960,319-114,092,980) × 1. The monosomy could be reﬂected by a shift in
Fig. 3. An example of SNP-PGD for one reciprocal translocation carrier with a karyotype of 46,XY,t(3;21)(q21;q22). E1 and E3 were normal/balanced embryos. E2 was a partial trisomy
3p26.3q21 and partial monosomy 21p11.2q22 (arrow). The SNP result of E2 was arr3p26.3q21 (48,602-121,264,951) × 1,21q10q22.11 (13,298,815-31,355,081) × 1. E4
carried abnormalities including partial trisomy 3q21q29, partial monosomy 21q22.12q22.3 and unrelated trisomy 15 (arrow). The SNP result of E4 was arr3q22.3q29
(138,633,205-199,318,809) × 3,(15) × 3,21q22.12q22.3(43,640,359-46,894,358) × 1. The partial monosomy could be reﬂected by a shift in the LOH probability of the SNPs toward
1 on the graph and the partial trisomy could be reﬂected by a greater frequency and distribution of all probes between 0 and 1 in the LOH probability graph.
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